Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.77 |
| ▸ | DPP8 | Q6V1X1 | 14/20 | 0.77 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.60 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.59 |
| ▸ | ACE | P12821 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | FAP | Q12884 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2667448 | 0.89 | DPP4 (0.75) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL14187434 | 0.85 | DPP4 (0.73) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL2667530 | 0.85 | DPP4 (0.77) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL8364024 | 0.84 | DPP4 (0.66) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL8364721 | 0.80 | DPP4 (0.76) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL13593626 | 0.80 | DPP4 (0.76) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL3845270 | 0.79 | DPP4 (0.89) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL8363512 | 0.79 | DPP4 (0.64) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL8362641 | 0.78 | DPP4 (0.60) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL8362642 | 0.78 | DPP4 (0.62) | DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080125403-A1 | Method of Treating Men with Metabolic and Anthropometric Disorders | MERCK & CO., INC. (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080125403-A1 | Method of Treating Men with Metabolic and Anthropometric Disorders | MERCK & CO., INC. (US) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125403-A1 | Method of Treating Men with Metabolic and Anthropometric Disorders | CYP17A1, SHBG, CYP21A2 | DPP4 158/4885DPP8 378/4885DPP9 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.